AbbVie Rival Boehringer Persuades PTAB To Reexamine Humira Patent
Executive Summary
Like Coherus BioSciences Inc., Boehringer Ingelheim GMBH convinced the US Patent & Trademark Office's Patent Trial and Appeal Board to back the company's inter partes review petition and institute a trial to consider the validity of certain claims on a patent held by AbbVie Inc. on its top-selling drug Humira (adalimumab), which also is facing competition from Amgen Inc., whose biosimilar application is under FDA review and is going before an advisory committee July 12.
You may also be interested in...
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.